Clinilabs Selected for a Phase I Study in Patients with Obstructive Sleep Apnea
Clinilabs
, a contract research organization that provides early-stage and specialty clinical drug development services to industry, announced that they have been selected to conduct a Phase I clinical research study of an investigational medication in patients with Obstructive Sleep Apnea (OSA).
Clinilabs has been involved in clinical research related to the development of sleep therapeutics for 20 years. Barbara Smallwood, Vice President of Business Development, states “We are proud to continue our part in the search for new treatments for sleep disorders, and we look forward to assessing the effects of an investigational new drug on patients with OSA.”
Enrollment for this study is expected to begin in April 2011. Referrals from physicians and other healthcare providers are welcomed. Individuals in the New York City Metro area who have been diagnosed with OSA can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting
www.clinilabs.com/OSA
.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
